Regulatory Rigor as a Competitive Moat: Interview with Osteoboost CEO Laura Yecies

Regulatory Rigor as a Competitive Moat: Interview with Osteoboost CEO Laura Yecies

From Medsider: Learn from Medtech and Healthtech Founders and CEOs by Scott Nelson

April 6, 2026 · 54 min

About this episode

Laura Yecies discusses regulatory strategies and commercialization in women's health with Scott Nelson.

In this episode of Medsider Radio , we sat down with Laura Yecies , CEO of Osteoboost . Osteoboost is the first FDA-cleared drug-free prescription treatment for osteopenia in postmenopausal women. Laura brings over 30 years of experience across technology, digital health, and medical innovation, with a focus on overlooked gaps in women's health. She previously served as CEO of SugarSync (acquired by J2 Global), Catchsold (sold to Apple), and Neurosync, a neurotechnology company. In this interview, Laura discusses why choosing a Class II prescription path creates a regulatory moat, how designing for daily comfort and a frictionless experience drives commercialization, and how channeling early patient demand turned a waitlist into a launch strategy. Before we dive into the discussion, I wanted to mention a few things: First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter. And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and…

More episodes of Medsider: Learn from Medtech and Healthtech Founders and CEOs

Explore listener stats, chart rankings, contacts and more on the Medsider: Learn from Medtech and Healthtech Founders and CEOs podcast page.